GRCE · NASDAQ
Grace Therapeutics (GRCE) Stock Price & Fundamentals
Grace Therapeutics (GRCE) closed at $1,291.86 on Oct 9, 2026, up 0.57% from the previous close of $1,284.53.
Share price, past year
1Y +16.66%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,291.86 |
| Sep 30, 2026 | $1,286.60 |
| Aug 31, 2026 | $1,224.66 |
| Jul 31, 2026 | $1,185.23 |
| Jun 30, 2026 | $1,276.62 |
| May 29, 2026 | $1,242.72 |
| Apr 30, 2026 | $1,145.11 |
| Mar 31, 2026 | $1,182.92 |
| Feb 27, 2026 | $1,133.27 |
| Jan 30, 2026 | $1,076.52 |
| Dec 31, 2025 | $1,093.76 |
| Nov 28, 2025 | $1,146.60 |
| Oct 31, 2025 | $1,104.25 |
Key statistics
- Market cap
- $21.02B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.32
- Revenue (TTM)
- —
- Net income (TTM)
- −$20.22M
- Shares outstanding
- 16.3M
- Dividend yield
- —
- 52-week range
- $1,056.32 – $1,321.89
Grace Therapeutics's market cap is $21.02B, based on a share price of $1,291.86 and 16.3M shares outstanding as of Jun 30, 2026.
Financials
Grace Therapeutics reported revenue of $100.00M for fiscal 2022, up 50,920.41% from fiscal 2021.
Grace Therapeutics reported a net loss of $7.79M in fiscal 2026.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2022ended Mar 31, 2022 | $100.00M | +50,920.4% | −$9.82M | −9.8% | −$0.27 | — |
| FY2021ended Mar 31, 2021 | $196.00K | — | −$19.68M | −10,039.8% | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2022ended Dec 31, 2021 | $0.00 | — | — |
| Q3 FY2021ended Dec 31, 2020 | $81.00K | — | — |
Company profile
- Name
- Grace Therapeutics, Inc.
- Ticker
- GRCE
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 103 Carnegie Center, Suite 300, Princeton, NJ 08540
- Incorporated in
- DE
- Fiscal year ends
- March
- SEC CIK
- 0001444192
Recent SEC filings
- Sep 18, 2026
- Aug 13, 2026
- Aug 13, 2026
- Aug 6, 2026
- Jul 28, 2026
- Jun 18, 2026
- Jun 18, 2026
- Jun 18, 2026
Frequently asked questions
What is Grace Therapeutics's stock price?
Grace Therapeutics (GRCE) closed at $1,291.86 on Oct 9, 2026, up 0.57% from the previous close of $1,284.53.
What is Grace Therapeutics's market cap?
Grace Therapeutics's market cap is $21.02B, based on a share price of $1,291.86 and 16.3M shares outstanding as of Jun 30, 2026.
How much revenue does Grace Therapeutics make?
Grace Therapeutics reported revenue of $100.00M for fiscal 2022, up 50,920.41% from fiscal 2021.
Does Grace Therapeutics pay a dividend?
Grace Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Grace Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures